Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 56 | ECE2018 | Next issue

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

Card image cap
ECE 2018, 19 - 22 May 2018; Barcelona, Spain

Oral Communications

New insights in bone disorders

ea0056oc3.1 | New insights in bone disorders | ECE2018

A Phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of Burosumab, an anti-FGF23 antibody, in adult X-Linked Hypophosphatemia (XLH)

Kamenicky Peter , Lachmann Robin , Carpenter Thomas O. , Cohen-Solal Martine , Eastell Richard , Brandi Maria Luisa , Crowley Rachel K. , Ralston Stuart H. , Javaid Muhammad K. , Keen Richard , Briot Karine , Il Cheong Hae , Imanishi Yasuo , Ito Nobuaki , Tanaka Hiroyuki , Zhang Lin , Theodore-Oklota Christina , Mealiffe Matt , Martin Javier San , Insogna Karl L.

UX023-CL303 is an ongoing, Phase 3, double-blind, multicenter study examining the efficacy and safety of burosumab, a fully human monoclonal antibody against FGF23, in adults with XLH. Eligible subjects had serum phosphorus levels <0.81 mmol/l and skeletal pain (BPI – Worst Pain ≥4). Subjects (N=134) were randomized 1:1 to receive burosumab 1 mg/kg or placebo subcutaneously every 4 weeks. After 24 weeks, subjects in the placebo group crossed-over to rec...

ea0056oc3.2 | New insights in bone disorders | ECE2018

Can a bone protein protect against muscular dystrophy?

Frenette Jerome

Receptor-activator of nuclear factor kB (RANK), its ligand RANKL and the soluble decoy receptor osteoprotegerin (OPG) are the key regulators of osteoclast differentiation and bone remodelling. Although there is a strong association between osteoporosis and skeletal muscle atrophy, the functional relevance of a particular biological pathway that regulates synchronously bone and skeletal muscle physiopathology remain elusive. We thus hypothesized that RANK/RANKL/OPG, which is a ...

ea0056oc3.3 | New insights in bone disorders | ECE2018

[18F]-FDG PET/CT imaging: A tool to reveal the metabolic functions of bone marrow adipose tissue

Suchacki Karla , Tavares Adriana , Sinton Matthew , Alcaide Carlos , Morton Nicholas , Cawthorn William

Introduction: White adipose tissue (WAT) and brown adipose tissue (BAT) are key regulators of systemic metabolic function. Bone marrow adipose tissue (BMAT) accounts for 10% of total adipose mass in healthy humans and therefore can be considered a third major adipose subtype. However, it is unclear if BMAT contributes to systemic energy homeostasis.Objectives: Assess [18F]-Fluorodeoxyglucose (FDG) uptake into bone and the marrow cavity (MC) fo...

ea0056oc3.4 | New insights in bone disorders | ECE2018

Renal function change in chronic hypoparathyroidism patients treated with recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and in a historical control cohort treated with standard therapy

Chen Kristina , Rubin Mishaela , Mu Fan , Swallow Elyse , Zhao Jing , Wang Jessie , Krasner Alan , Sherry Nicole , Signorovitch James , Ketteler Markus , Bilezikian John

Standard therapy (ST) for chronic hypoparathyroidism (HPT) includes calcium and active vitamin D supplementation, which can be associated with an increased risk of renal complications. This study compared renal function change, assessed by estimated glomerular filtration rate (eGFR) over 5 years between HPT patients receiving rhPTH1-84 as an adjunct to ST and a historical control cohort without rhPTH1-84. rhPTH1-84-treated HPT patients were selected from two single-arm, long-t...

ea0056oc3.5 | New insights in bone disorders | ECE2018

Change in bone mineral density during the first 10 years of gender affirming hormonal treatment in transwomen and transmen

Wiepjes Chantal , de Blok Christel , Vlot Mariska , de Jongh Renate , Lips Paul , den Heijer Martin

Background: Concerns about the effects of gender affirming hormonal treatment (HT) on bone mineral density (BMD) exists, particularly for transmen with decreasing estrogen levels. HT in transpersons affects BMD on short term, but long-term follow-up studies are lacking. Therefore this study aimed to investigate the change in BMD during the first 10 years of HT in adult transwomen and transmen, in order to determine whether it is necessary to assess BMD during HT.<p class="...